TNXP
Tonix Pharmaceuticals Holding Corp.
$11.46
-2.13%
$186.7M
No data for this timeframe.
Vol
Market Cap$186.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders6 funds
Inst. Value$12.4M
Inst. Activity3 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$403.6K
Reddit Sentiment57° Neutral
SEC Reports7
Press Releases8
Recent Activity
Jun 9, 2026
SEC
CEO Seth Lederman and Director Richard Stillwell each purchased $59K and $58K worth of TNXP shares in open-market transa
CLUSTER — Impact 4/10
Jun 9, 2026
Insider
LEDERMAN SETH bought 5,000 shares
Chief Executive Officer @ $11.79 ($58.9K)
Jun 8, 2026
SEC
Tonix Pharmaceuticals announced a second GPO agreement for TONMYA, effective June 1, 2026, adding ~17 million commercial
8-K — Impact 4/10
Jun 8, 2026
other
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
<p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective J
Jun 8, 2026
Insider
Stillwell Richard Newcomb bought 5,000 shares
Director @ $11.65 ($58.3K)
May 15, 2026
SEC
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody to prevent Lyme disease, at
8-K — Impact 6/10
May 12, 2026
Insider
BAGGER RICHARD H sold 22,700 shares
Director @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
42,038 shares ($656.6K)
Price Targets
$46.25
+303.6% upside
Strong Buy
Current $11.46
Low $22.00
Median $49.00
High $65.00
4 analysts
$22.00
$65.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | TD Cowen | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.62 ▼ -9.4% | $-2.76 — $-2.48 | 35% YoY | 2 |
| Next Q | $-2.41 ▼ -1.5% | $-2.53 — $-2.29 | 35% YoY | 2 |
| Current FY | $-10.10 ▼ -7.4% | $-10.60 — $-9.60 | 31% YoY | 2 |
| Next FY | $-7.80 ▼ -1.0% | $-8.35 — $-7.25 | 23% YoY | 2 |
Latest Reports
BULLISH
CLUSTER
4/10
CEO Seth Lederman and Director Richard Stillwell each purchased $59K and $58K worth of TNXP shares in open-market transa
Jun 9, 2026
NEUTRAL
8-K
4/10
Tonix Pharmaceuticals announced a second GPO agreement for TONMYA, effective June 1, 2026, adding ~17 million commercial
Jun 8, 2026
NEUTRAL
Press
2/10
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 on a retrospective claims study characterizing fibro
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $10.5M | DOUBLED |
| MORGAN STANLEY | $656.6K | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $521.8K | NEW |
| BANK OF AMERICA CORP | $473.5K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $241.0K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | LEDERMAN SETH | BUY | $58.9K |
| Jun 8, 2026 | Stillwell Richard | BUY | $58.3K |
| May 12, 2026 | BAGGER RICHARD | A | $0.00 |
| May 12, 2026 | Taylor Carolyn | A | $0.00 |
| May 12, 2026 | GRANGE DAVID | A | $0.00 |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $12.4M total value (796,295 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 673,605 | $10.5M | 84.6% | DOUBLED +238.1% |
| 2 | MORGAN STANLEY | 42,038 | $656.6K | 5.3% | DOUBLED +168.2% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 33,404 | $521.8K | 4.2% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 30,314 | $473.5K | 3.8% | DOUBLED +551.8% |
| 5 | WELLS FARGO & COMPANY/MN | 15,430 | $241.0K | 1.9% | DOUBLED +114.6% |
| 6 | FMR LLC | 1,504 | $23.5K | 0.2% | NEAR_EXIT -96.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 15,675 | 42,038 | +168.2% | $656.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,651 | 30,314 | +551.8% | $473.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 7,190 | 15,430 | +114.6% | $241.0K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 45,466 | 1,504 | -96.7% | $23.5K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 164,732 | 556,957 | +238.1% | $13.5M | 2025-Q3 |
| UBS Group AG | DOUBLED | 22,463 | 51,581 | +129.6% | $1.2M | 2025-Q3 |
| FMR LLC | DOUBLED | 12,753 | 45,466 | +256.5% | $1.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 4,856 | 7,190 | +48.1% | $173.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 3,505 | 4,651 | +32.7% | $112.4K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 91,496 | 164,732 | +80.0% | $5.9M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 21,732 | — | $781.9K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 2,677 | 18,928 | +607.1% | $681.0K | 2025-Q2 |
| FMR LLC | NEW | — | 12,753 | — | $458.9K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 4,856 | — | $174.7K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 5,760 | 3,505 | -39.1% | $126.1K | 2025-Q2 |
| VANGUARD GROUP INC | NEW | — | 91,496 | — | $1.6M | 2025-Q1 |
| UBS Group AG | NEW | — | 19,969 | — | $356.9K | 2025-Q1 |
| MORGAN STANLEY | NEW | — | 2,677 | — | $47.9K | 2025-Q1 |
13 unique insiders with 4 transactions. Net insider value: $403.6K ($403.6K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | LEDERMAN SETH | Chief Executive Officer | BUY | 5,000 | $11.79 | $58.9K |
| Jun 8, 2026 | Stillwell Richard Newcomb | Director | BUY | 5,000 | $11.65 | $58.3K |
| May 12, 2026 | BAGGER RICHARD H | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | Taylor Carolyn E. | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | GRANGE DAVID L | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | Treco James | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | Hunter James Randolph Jr | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | OLUKOTUN ADEOYE Y | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | Stillwell Richard Newcomb | Director | A | 22,700 | $0.00 | $0.00 |
| May 12, 2026 | Bell Margaret Smith | Director | A | 22,700 | $0.00 | $0.00 |
| Mar 31, 2026 | LEDERMAN SETH | Chief Executive Officer | BUY | 5,000 | $12.62 | $63.1K |
| Mar 18, 2026 | LEDERMAN SETH | Chief Executive Officer | BUY | 15,000 | $14.89 | $223.3K |
| Feb 24, 2026 | SULLIVAN GREGORY M | Chief Medical Officer | A | 39,012 | $0.00 | $0.00 |
| Feb 24, 2026 | MORRIS JESSICA EDGAR | Chief Operating Officer | A | 39,012 | $0.00 | $0.00 |
| Feb 24, 2026 | Fogarty Siobhan | Chief Technology Officer | A | 39,012 | $0.00 | $0.00 |
| Feb 24, 2026 | SAENGER BRADLEY | Chief Financial Officer | A | 39,012 | $0.00 | $0.00 |
| Feb 24, 2026 | LEDERMAN SETH | Chief Executive Officer | A | 134,504 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 2 mixed, 2 neutral. Avg impact: 5.0/10.
BULLISH
CLUSTER
4/10
CEO Seth Lederman and Director Richard Stillwell each purchased $59K and $58K worth of TNXP shares i
Jun 9, 2026
NEUTRAL
8-K
4/10
Tonix Pharmaceuticals announced a second GPO agreement for TONMYA, effective June 1, 2026, adding ~1
Jun 8, 2026
BULLISH
8-K
6/10
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody to prev
May 15, 2026
BEARISH
8-K
6/10
Tonix Pharmaceuticals reported Q1 2026 revenue of $6.9M, up 183% YoY from $2.4M, driven by the TONMY
May 11, 2026
NEUTRAL
8-K
4/10
Tonix Pharmaceuticals announced Phase 1 data for TNX-4800, a monoclonal antibody for Lyme disease pr
Apr 29, 2026
MIXED
8-K
5/10
Tonix Pharmaceuticals presented preclinical data at the AACR 2026 conference showing that TNX-1700 r
Apr 23, 2026
MIXED
8-K
6/10
Tonix Pharmaceuticals reported its 2025 financial results, highlighting the commercial launch of TON
Mar 13, 2026
NEUTRAL
2/10
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 on a retrospective claims study
May 14, 2026
NEUTRAL
4/10
Tonix Pharmaceuticals announced the publication of a peer-reviewed pharmacokinetic study supporting
Apr 15, 2026
NEUTRAL
5/10
Tonix Pharmaceuticals announced the first participant dosed in a Phase 1 investigator-initiated stud
Mar 26, 2026
NEUTRAL
5/10
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody for sea
Mar 23, 2026
NEUTRAL
3/10
Tonix Pharmaceuticals announced upcoming presentations at the AACR Annual Meeting 2026 on its precli
Mar 17, 2026
BULLISH
7/10
Tonix Pharmaceuticals presented new Phase 3 data at the 2026 AAPM PainConnect Annual Meeting support
Mar 9, 2026
BULLISH
8/10
Tonix Pharmaceuticals announced the publication of pharmacokinetic data supporting TONMYA (cyclobenz
Mar 5, 2026
NEUTRAL
4/10
Tonix Pharmaceuticals has been approved to uplist its common stock from the Nasdaq Capital Market to
Mar 3, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$46.25 mean target
+303.6% upside
Strong Buy (1.00)
$22.00 Low
$65.00 High
| Metric | Value |
|---|---|
| Current Price | $11.46 |
| Target Low | $22.00 |
| Target Mean | $46.25 |
| Target Median | $49.00 |
| Target High | $65.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.62 | $-2.76 | $-2.48 | 34.5% | -9.4% | — | $0.0B | 248.5% | 2 |
| Next Q 2026-09-30 |
$-2.41 | $-2.53 | $-2.29 | 34.8% | -1.5% | 0↑ 1↓ | $0.0B | 142.6% | 2 |
| Current FY 2026-12-31 |
$-10.10 | $-10.60 | $-9.60 | 31.2% | -7.4% | 0↑ 1↓ | $0.0B | 135.8% | 2 |
| Next FY 2027-12-31 |
$-7.80 | $-8.35 | $-7.25 | 22.8% | -1.0% | 0↑ 1↓ | $0.1B | 161.7% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.620 | |
| 7d ago | $-2.620 | |
| 30d ago | $-2.395 | -0.225 |
| 60d ago | $-2.290 | -0.330 |
| 90d ago | $-2.290 | -0.330 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | TD Cowen | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 6, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Jun 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
$TNXP Tonmya sets New High in weekly Sales
▲ 1
💬 1
⚡ 0.5
TNXP weekly Sales update Set Record High
▲ 1
💬 0
⚡ 0.5
Jun 8, 2026
other
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
<p align="center"><em>Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 m
May 28, 2026
routine
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
<p align="center"><em>Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024
May 26, 2026
routine
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
<p align="center"><em>Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024)
May 14, 2026
fda
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
<p>BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully i
May 12, 2026
other
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
<p align="left">BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company
May 11, 2026
earnings
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
<p align="center"><em>In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA<sup>®</sup>, 3,588 patients initiated treat
May 11, 2026
earnings_calendar
TNXP Q1 2026 Earnings Scheduled — 2026-05-11
Apr 16, 2026
short_interest
FTD: TNXP — 137,748 shares ($2.0M) failed to deliver
Settlement: 20260416, Price: $14.34, FTD Value: $1,975,306.32, TONIX PHARMACEUTICALS HLDG COR
Apr 15, 2026
fda
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
<p align="center"><em>TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment f
Apr 9, 2026
short_interest
FTD: TNXP — 191,418 shares ($2.5M) failed to deliver
Settlement: 20260409, Price: $13.04, FTD Value: $2,496,090.72, TONIX PHARMACEUTICALS HLDG COR
Mar 26, 2026
fda
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
<p align="center"><em>Intranasal oxytocin blocks the release of calcitonin gene-related peptide</em> (<em>CGRP) in animal models and is the core techn
Mar 23, 2026
fda
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
<p align="center"><em>Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal preventio
Mar 23, 2026
short_interest
FTD: TNXP — 184,620 shares ($2.8M) failed to deliver
Settlement: 20260323, Price: $15.00, FTD Value: $2,769,300, TONIX PHARMACEUTICALS HLDG COR
Mar 18, 2026
other
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
<p>BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully
Mar 17, 2026
fda
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
<p align="left">BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Compa